L-DOPA
Compiled from published pharmacological and botanical literature. Not independently verified by Herbuno. Spotted an error or have a correction? Flag it below →
| Chemical Class | Non-proteinogenic amino acid (catecholamine precursor) |
| Molecular Formula / CAS | C₉H₁₁NO₄ · CAS 59-92-7 |
| Primary Botanical Source(s) | Velvet bean / kaunch beej (Mucuna pruriens) |
| Plant Part | Seed |
| Typical Content | Mucuna seed carries L-DOPA at roughly 4–6% of seed weight, making it the richest known botanical source |
| Solubility / Format | Water-soluble amino acid; available as high-purity isolate and standardised extract powders |
| Sourcing Status | Product-live — genuine match via Herbuno’s velvet bean-derived L-DOPA extract line |
| Buy from Herbuno | L-DOPA 98% Powder (High-Purity Isolate) · L-DOPA 50% Powder (Standardized Extract) |
Name origin: L-DOPA is short for L-3,4-dihydroxyphenylalanine, describing its chemical structure as a hydroxylated derivative of the amino acid phenylalanine/tyrosine, and it is also widely known by its pharmaceutical name levodopa. Traditional use: Mucuna pruriens, known as kaunch beej in Ayurvedic tradition, has been used for centuries in Indian medicine specifically for tremor and movement-related conditions that modern medicine would recognise as parkinsonian symptoms — a striking case of traditional use anticipating a mechanism that was only scientifically confirmed decades later. Research trajectory: L-DOPA was first isolated from Mucuna seed in 1937, well before its role as the direct dopamine precursor and its therapeutic significance for Parkinson’s disease were established; once levodopa became the gold-standard pharmaceutical treatment for Parkinson’s disease in the late 1960s, research attention returned to Mucuna specifically as a potential low-cost, naturally sourced alternative delivery route, particularly relevant in regions with limited access to pharmaceutical levodopa. Commercial source: Velvet bean is the standard commercial source of L-DOPA, and Herbuno’s standardised extracts reflect this well-established, genuine botanical match.
Evidence for L-DOPA Applications
L-DOPA is the direct metabolic precursor to dopamine, converted by the enzyme aromatic L-amino acid decarboxylase (also called DOPA decarboxylase). Because dopamine itself cannot cross the blood-brain barrier but L-DOPA can, oral L-DOPA administration is the foundational mechanism behind levodopa pharmaceutical therapy for Parkinson’s disease, a condition characterised by progressive loss of dopamine-producing neurons. Claim strength: High.
A landmark double-blind, randomised, controlled crossover trial directly compared Mucuna seed powder preparations against standard pharmaceutical levodopa/carbidopa in Parkinson’s disease patients with motor fluctuations, finding that higher-dose Mucuna preparations produced a faster onset of clinical effect and a longer duration of benefit than standard levodopa/carbidopa at equivalent L-DOPA content, with no difference in dyskinesia severity between treatments (Katzenschlager et al. 2004). This head-to-head pharmacokinetic and clinical comparison remains one of the most cited pieces of Mucuna-specific human evidence. Claim strength: Moderate.
A 12-month, multicenter, randomised controlled trial conducted in sub-Saharan Africa — a region where pharmaceutical levodopa access is often limited — compared long-term Mucuna powder-derived L-DOPA against standard levodopa plus dopa-decarboxylase inhibitor therapy in previously untreated Parkinson’s disease patients, testing non-inferiority in safety and efficacy over a full year of treatment (Cilia et al. 2026). This represents a substantially longer treatment duration than most prior Mucuna research, which has historically focused on single-dose or short-term comparisons. Claim strength: Moderate.
A 2025 systematic review of clinical trials evaluating Mucuna pruriens for Parkinson’s disease identified five qualifying trials involving 108 total participants, with quality assessment rating the evidence base as mixed — one trial rated high quality, one with some concerns, and three rated low quality (Hammoud et al. 2025). This underscores that while Mucuna-derived L-DOPA has real, mechanistically sound clinical trial support, the overall evidence base remains smaller and more variable in quality than the pharmaceutical levodopa literature it is compared against. Claim strength: Moderate.
For formulators, the critical practical point is that Mucuna-derived L-DOPA is pharmacologically active in the same way as pharmaceutical levodopa — it is not a gentler, inherently safer “natural” alternative exempt from the drug interactions, dosing precision requirements, or side-effect profile associated with levodopa therapy. Any formulation or marketing involving L-DOPA-standardised Mucuna extract should reflect this pharmacological reality rather than positioning it as a conventional low-risk botanical supplement. Claim strength: High.
Dosage & Formulator Specification
Clinical research doses of Mucuna-derived L-DOPA in Parkinson’s disease trials have ranged from roughly 200 mg to over 600 mg of L-DOPA per single dose, generally combined with careful titration and, in several trials, alongside a peripheral decarboxylase inhibitor as is standard pharmaceutical levodopa practice; these are clinical-trial protocols for a diagnosed neurological condition, not general dietary supplement guidance.
Analytical quantification of L-DOPA content is performed by HPLC, the standard method used across both the Mucuna botanical literature and pharmaceutical levodopa quality control; formulators should request HPLC-verified L-DOPA percentage given the clinical significance of accurate potency labelling for this compound.
Because L-DOPA is metabolically identical to pharmaceutical levodopa, it carries the same well-documented interaction profile: concurrent use with MAO inhibitors, certain antipsychotics, and other dopaminergic or antidopaminergic medications requires clinical caution, and any product containing standardised Mucuna L-DOPA extract should carry appropriate interaction and consultation guidance rather than being positioned as a routine wellness ingredient.
Regulatory positioning for Mucuna-derived L-DOPA varies by market given its pharmacological equivalence to a prescription drug active ingredient; some jurisdictions restrict or specifically regulate L-DOPA-standardised botanical extracts differently from generic herbal supplements. Formulators should verify local regulatory status for L-DOPA-containing products in each target market before finalising label claims.
Frequently Asked Questions — L-DOPA
Yes, chemically identical. L-DOPA extracted from Mucuna pruriens seed is the same molecule as the levodopa used in prescription Parkinson’s disease medication, and it carries the same pharmacological activity, dosing considerations, and interaction profile as the pharmaceutical form.
Several clinical trials, including a landmark double-blind crossover study and a 12-month randomized controlled trial, have directly compared Mucuna preparations against standard pharmaceutical levodopa in Parkinson’s patients. A 2025 systematic review found the overall evidence base promising but of mixed methodological quality across the available trials.
Mucuna pruriens, known as kaunch beej, has been used in Ayurvedic tradition for centuries specifically for tremor and movement conditions, which modern science later explained through its high natural L-DOPA content and direct action on the dopamine pathway affected in Parkinson’s disease.
No. Because L-DOPA is pharmacologically identical to prescription levodopa, it carries real drug interaction risks, particularly with MAO inhibitors and certain psychiatric medications. Products containing standardised L-DOPA extract should include appropriate interaction guidance rather than being marketed as a routine low-risk botanical.
Related compounds: Diosgenin, Hordenine